This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pourquier, P. Articles by Pommier, Y. Search for Related Content PubMed PubMed Citation Articles by Pourquier, P. Articles by Pommier, Y.

Gemcitabine (2',2'-Difluoro-2'-Deoxycytidine), an Antimetabolite That Poisons Topoisomerase I

Laboratory of Molecular Pharmacology, Division of Basic Sciences, NCI, National Institutes of Health, Bethesda, Maryland [P. P., C. G., G. K., Y. U., Y. M., Y. P.]; Unité d’oncologie médicale, Hôpital Cochin, Paris, France [F. G.]; Cancer Research Division, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana [L. W. H.]; Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, North-Carolina [W. H. G.]; Core DNA Synthesis Facility, University of Calgary, Calgary, Alberta, Canada [S. Y., R. T. P.]

Purpose: Gemcitabine-containing regimens are among standard therapies for the treatment of advanced non-small cell lung,pancreatic, or bladder cancers. Gemcitabine is a nucleoside analogue and its cytotoxicity is correlated with incorporation into genomic DNA and concomitant inhibition of DNA synthesis. However, it is still unclear by which mechanism(s) gemcitabine incorporation leads to cell death.

Experimental Design: We used purified oligodeoxynucleotides to study the effects of gemcitabine incorporation on topoisomerase I (top1) activity and tested the role of top1 poisoning in gemcitabine-induced cytotoxicity in cancer cells.

Results: We found that top1-mediated DNA cleavage was enhanced when gemcitabine was incorporated immediately 3' from a top1 cleavage site on the nonscissile strand. This position-specific enhancement was attributable to an increased DNA cleavage by top1 and was likely to have resulted from a combination of gemcitabine-induced conformational and electrostatic effects. Gemcitabine also enhanced camptothecin-induced cleavage complexes. We also detected top1 cleavage complexes in human leukemia CEM cells treated with gemcitabine and a 5-fold resistance of P388/CPT45 top1-deficient cells to gemcitabine, indicating that poisoning of top1 can contribute to the antitumor activity of gemcitabine.

Conclusions: The present results extend our recent finding that incorporation of 1-ß-D-arabinofuranosylcytosine into DNA can induce top1 cleavage complexes [P. Pourquier et al. Proc. Natl. Acad. Sci. USA, 97: 1885–1890, 2000]. The enhancement of camptothecin-induced top1 cleavage complexes may, at least in part, contribute to the synergistic or additive effects of gemcitabine in combination with topotecan and irinotecan in human breast or lung cancer cells.

This article has been cited by other articles:

				M. Galvez-Peralta, N. T. Dai, D. A. Loegering, K. S. Flatten, S. L. Safgren, J. M. Wagner, M. M. Ames, L. M. Karnitz, and S. H. Kaufmann Overcoming S-Phase Checkpoint-Mediated Resistance: Sequence-Dependent Synergy of Gemcitabine and 7-Ethyl-10-hydroxycamptothecin (SN-38) in Human Carcinoma Cell Lines Mol. Pharmacol., September 1, 2008; 74(3): 724 - 735. [Abstract] [Full Text] [PDF]

				T. Yeo, J Kintner, R Armand, R Perez, and L. Lewis Sublethal concentrations of gemcitabine (2',2'-difluorodeoxycytidine) alter mitochondrial ultrastructure and function without reducing mitochondrial DNA content in BxPC-3 human pancreatic carcinoma cells Human and Experimental Toxicology, December 1, 2007; 26(12): 911 - 921. [Abstract] [PDF]

				D. S. Kalinowski and D. R. Richardson The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer Pharmacol. Rev., December 1, 2005; 57(4): 547 - 583. [Abstract] [Full Text] [PDF]

				Z.-Y. Liao, O. Sordet, H.-L. Zhang, G. Kohlhagen, S. Antony, W. H. Gmeiner, and Y. Pommier A Novel Polypyrimidine Antitumor Agent FdUMP[10] Induces Thymineless Death with Topoisomerase I-DNA Complexes Cancer Res., June 1, 2005; 65(11): 4844 - 4851. [Abstract] [Full Text] [PDF]

				B. Pauwels, A. E.C. Korst, F. Lardon, and J. B. Vermorken Combined Modality Therapy of Gemcitabine and Radiation Oncologist, January 1, 2005; 10(1): 34 - 51. [Abstract] [Full Text] [PDF]

				T. E. Kim, S.-Y. Park, C.-H. Hsu, G. E. Dutschman, and Y.-C. Cheng Synergistic Antitumor Activity of Troxacitabine and Camptothecin in Selected Human Cancer Cell Lines Mol. Pharmacol., August 1, 2004; 66(2): 285 - 292. [Abstract] [Full Text] [PDF]

				K. Soe and F. Grosse p53 stimulates human topoisomerase I activity by modulating its DNA binding Nucleic Acids Res., November 15, 2003; 31(22): 6585 - 6592. [Abstract] [Full Text] [PDF]